@article {8231,
	title = {Fludarabine therapy in Waldenstr{\"o}m{\textquoteright}s macroglobulinemia},
	journal = {The American Journal of Medicine},
	volume = {95},
	year = {1993},
	note = {Cited By :87Export Date: 21 February 2017},
	month = {1993},
	pages = {49 - 52},
	abstract = {purpose: To assess the response rate, remission duration, and survival of patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia treated with the adenine nucleoside analogue fludarabine. patients and methods: Twenty-eight patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinernia, of whom only 2 were previously untreated, received fludarabine at a dose of 20 to 30 mg/m2 intravenously daily for 5 days (20 patients) or 30 mg/m2 intravenously daily for 3 days (8 patients). Treatment was continued until maximum response was achieved. Responding patients were followed with no further treatment until relapse. results: Ten patients responded (36\%), including the 2 previously untreated patients and 8 of 26 patients (31\%) who were resistant to prior therapies. Uninaintained remissions lasted for a median of 38 months. There were no fatalities associated with this treatment. Previously untreated patients and those with a primary resistant disease of relatively short duration were more likely to benefit from this treatment. conclusion: Fludarabine is an effective salvage agent for the treatment of patients with resistant Waldenstr{\"o}m{\textquoteright}s macroglobulinemia. Further investigations of fludarabine in untreated patients and in combination with other active agents are warranted. {\textcopyright} 1993.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027337283\&doi=10.1016\%2f0002-9343\%2893\%2990231-D\&partnerID=40\&md5=5bfdbd77979fa459ff03907971185222},
	author = {Dimopoulos, M.A. and O{\textquoteright}Brien, S. and Kantarjian, H. and Pierce, S. and Delasalle, K. and Barlogie, B. and Alexanian, R. and Keating, M.J.}
}
